Dermata Therapeutics (DRMA) Competitors $1.17 +0.01 (+0.86%) (As of 02:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends DRMA vs. SNOA, ONCO, EGRX, AYTU, VINC, JAGX, RDHL, SNGX, ADXN, and MBRXShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Sonoma Pharmaceuticals (SNOA), Onconetix (ONCO), Eagle Pharmaceuticals (EGRX), Aytu BioPharma (AYTU), Vincerx Pharma (VINC), Jaguar Health (JAGX), RedHill Biopharma (RDHL), Soligenix (SNGX), Addex Therapeutics (ADXN), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Sonoma Pharmaceuticals Onconetix Eagle Pharmaceuticals Aytu BioPharma Vincerx Pharma Jaguar Health RedHill Biopharma Soligenix Addex Therapeutics Moleculin Biotech Dermata Therapeutics (NASDAQ:DRMA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Do insiders and institutionals believe in DRMA or SNOA? 8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 9.4% of Dermata Therapeutics shares are held by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor DRMA or SNOA? Sonoma Pharmaceuticals received 211 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 50.00% of users gave Dermata Therapeutics an outperform vote. CompanyUnderperformOutperformDermata TherapeuticsOutperform Votes550.00% Underperform Votes550.00% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Which has better valuation & earnings, DRMA or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Dermata Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$7.80M-$16.41-0.07Sonoma Pharmaceuticals$12.73M0.32-$4.84M-$4.99-0.60 Is DRMA or SNOA more profitable? Dermata Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -27.21%. Sonoma Pharmaceuticals' return on equity of -59.58% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -247.39% -179.72% Sonoma Pharmaceuticals -27.21%-59.58%-24.33% Does the media prefer DRMA or SNOA? In the previous week, Dermata Therapeutics had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for Sonoma Pharmaceuticals. Dermata Therapeutics' average media sentiment score of 1.50 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Dermata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dermata Therapeutics Very Positive Sonoma Pharmaceuticals Neutral Do analysts rate DRMA or SNOA? Dermata Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 412.82%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, DRMA or SNOA? Dermata Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. SummaryDermata Therapeutics beats Sonoma Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.39M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-0.075.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book0.5010.276.976.37Net Income-$7.80M$153.22M$118.73M$225.56M7 Day Performance-1.60%-1.19%-1.22%-0.02%1 Month Performance-25.00%-6.71%-3.07%2.04%1 Year Performance-90.13%32.39%32.52%28.00% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics2.2798 of 5 stars$1.17+0.9%$6.00+412.8%-90.7%$2.39MN/A-0.078Positive NewsSNOASonoma Pharmaceuticals0.839 of 5 stars$3.00+5.6%N/A+1,381.5%$4.02M$12.73M0.00180ONCOOnconetix0.2078 of 5 stars$1.11+2.8%N/AN/A$9.20M$60,000.000.0012EGRXEagle Pharmaceuticals1.1175 of 5 stars$0.70+7.3%N/A-92.5%$9.09M$316.61M0.00134Analyst ForecastGap UpAYTUAytu BioPharma1.33 of 5 stars$1.47-1.3%N/A-37.9%$9.04M$81M-1.21160VINCVincerx Pharma2.9731 of 5 stars$0.27-3.8%$2.00+654.1%-60.6%$8.90MN/A0.0060JAGXJaguar Health0.6718 of 5 stars$0.96-2.0%N/A-96.5%$8.87M$9.76M0.0050RDHLRedHill Biopharma0.9881 of 5 stars$6.79+6.1%N/A-96.9%$8.69M$6.53M0.00210News CoverageSNGXSoligenix0.9628 of 5 stars$3.46-1.4%N/A-49.0%$8.69M$840,000.000.0020ADXNAddex Therapeutics2.6699 of 5 stars$8.13+10.2%$30.00+269.0%+23.6%$8.62M$1.83M0.0030Gap UpMBRXMoleculin Biotech3.0386 of 5 stars$2.67flat$31.00+1,061.0%-67.1%$8.01MN/A0.0020Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies SNOA Competitors ONCO Competitors EGRX Competitors AYTU Competitors VINC Competitors JAGX Competitors RDHL Competitors SNGX Competitors ADXN Competitors MBRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRMA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
